Abstract 5760
Background
PD-L1 expression was approved by U.S. FDA as companion or complementary diagnostic for most anti-PD-1/ PD-L1 inhibitors, which is well accepted as one of the important biomarkers in the selection of patients who would have high potential to respond. By far, the PD-L1 prevalence in Chinese solid tumor patients is poorly reported. In lung cancer, the correlation between PD-L1 expression and another important biomarker tumor mutation burden (TMB) has been demonstrated to be weak, however, the results in other types of solid tumor are still limited, which needs further explorations.
Methods
A total of 6,571 Chinese solid tumor patients, including 1,534 lung cancer patients and 5,037 other solid tumor patients, from 70 sites were studied. The tissue samples, either surgical resection specimens or biopsy samples, were both stained by clinical validated PD-L1 IHC assay and performed the next generation sequencing (NGS) using a validated commercial 381-cancer-gene panel, with panel size over 0.5 MB. TMB was calculated according to NGS results.
Results
835 of 1534 (54.4%) lung cancer patients had PD-L1 expression >1% on tumor cells. The PD-L1 prevalence in NSCLC, small cell lung cancer, squamous cell carcinoma, adenocarcinoma and adenosine squamous cell carcinoma were 55.4%, 16.1%, 64.2%, 52.7% and 66.7%, respectively. Among 5,037 non-lung solid tumor patients, the proportion of PD-L1 expression >1% is 28.4%, 23.5%, 38.9%, 29.5%, 60% and 37.1% in gastric cancer, colorectal cancer, hepatobiliary cancer, urologic cancer, head and neck cancer and gynecological cancer. The average TMB of PD-L1 expression >1% solid tumor patients (excluding lung cancer) was 10.87/ MB, which is statistically significant higher than PD-L1 expression <1% subgroup (8.64/MB, p = 2.5e-06).
Conclusions
The PD-L1 prevalence varied in different tumor type subgroups. And TMB was significant different between PD-L1 expression >1% and <1% subgroups. But, the correlation between PD-L1 and TMB needs more studies, which is important to reveal whether these two biomarkers are mutually independent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
3D Medicine, Shanghai.
Funding
3D Medicine, Shanghai.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract